About Emtora Biosciences
Emtora Biosciences is a Healthcare company based in San Antonio (United States) founded in 2009. Reformulated therapies for cancers and age-related disorders are developed. Emtora Biosciences has raised $2.5 million across 5 funding rounds from investors including Metric Medical Devices, CPRIT and UT Horizon Fund. Emtora Biosciences offers products and services including eRapa. Its focus areas include Life Sciences, Oncology, Drugs and Prostate Cancer. Its competitors include Radionetics, Convergent Therapeutics and Madison Vaccines; 3 of its 3 listed competitors have raised funding.
Company details
Emtora Biosciences is reformulating therapies for treating cancers and other age-related disorders. They have developed eRapa which is a formulation of rapamycin that can extend life by delaying the onset of aging-related diseases such as cancer. The lead candidate is in phase I clinical trial. It is being investigated for Familial Adenomatous Polyposis (a genetic condition that increases the risk of colon cancer).
- Headquarters San Antonio, United States
- SectorsHealthcare
- Phone•••• ••••
- Website emtorabio.com
- Social LinkedIn
- Total Equity Funding$2.5M (USD)
in 5 rounds
- Latest Funding Round$16.9M (USD), Grant
Aug 2022
- InvestorsMetric Medical Devices
& 2 more
Products & Services of Emtora Biosciences
Emtora Biosciences offers a comprehensive portfolio of products and services, including eRapa.
Formulation of rapamycin for cancer and rare disease treatment.
Funding Insights of Emtora Biosciences
Emtora Biosciences has successfully raised a total of $2.5M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $16.9 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 5
- Last Round Grant — $16.9M
- Investors Count 3
All 5 funding rounds of Emtora Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $16.9M | Grant | – | – | |
| Aug 2019 | $3M | Grant | – | – | |
| Jun 2015 | $2.5M | Series A | – | – | – |
| Feb 2014 | $1.43M | Debt – Conventional | – | – | – |
| Dec 2012 | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Emtora Biosciences
Emtora Biosciences has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Metric Medical Devices, CPRIT and UT Horizon Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| cprit.texas.gov | ||||
| uthorizons.com | ||||
Orthopedic implant systems for musculoskeletal fixation are developed. | 2009 | metricmd.com | Helotes, United States |
Investor details for Emtora Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Emtora Biosciences
3 dated milestones of Emtora Biosciences across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Emtora Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $16.9M.
Competitors of Emtora Biosciences
Emtora Biosciences has 3 listed competitors in our database, 3 of them funded. They include Radionetics, Convergent Therapeutics and Madison Vaccines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| radionetics.com | 2021 | San Diego, United States | $136.71M | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. | ||
| convergentrx.com | 2020 | United States | $130M | 4 | Cancer therapeutics are developed using dual-targeted radionuclide therapy. | |
| madisonvaccines.com | 2012 | Madison, United States | $18M | Immunotherapies for prostate cancer treatment are developed. |
Detailed competitors of Emtora Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Emtora Biosciences
The website of Emtora Biosciences (emtorabio.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 11.2% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Emtora Biosciences (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Emtora Biosciences
Complete news archive for Emtora Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emtora Biosciences
Emtora Biosciences was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Emtora Biosciences is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Emtora Biosciences is a funded company, having raised a total of $2.5M across 5 funding rounds to date.
Emtora Biosciences is reformulating therapies for treating cancers and other age-related disorders. They have developed eRapa which is a formulation of rapamycin that can extend life by delaying the onset of aging-related diseases such as cancer. The lead candidate is in phase I clinical trial. It is being investigated for Familial Adenomatous Polyposis (a genetic condition that increases the risk of colon cancer).
Emtora Biosciences's top competitors include Radionetics, Convergent Therapeutics and Madison Vaccines.
Emtora Biosciences offers eRapa.
Emtora Biosciences has 3 investors. Key investors include Metric Medical Devices, CPRIT, and UT Horizon Fund.